



(12) Translation of
european patent specification

(11) NO/EP 2719699 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 487/04 (2006.01)
A61K 31/437 (2006.01)
A61K 31/4985 (2006.01)
A61P 35/00 (2006.01)
C07D 471/04 (2006.01)
C07D 519/00 (2006.01)

Norwegian Industrial Property Office







(21)	Translation Published	2015.10.26
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.07.08
(86)	European Application Nr.	13198224.1
(86)	European Filing Date	2010.12.30
(87)	The European Application's Publication Date	2014.04.16
(30)	Priority	2009.12.31, WO, PCT/CN09/076321
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Hutchison Medipharma Limited, 720 Cai Lun Road Building 4, Pudong, Shanghai 201203, CN-Kina
(72)	Inventor	Su, Wei-Guo, 720 Cai Lun Road Building 4, Pudong Shanghai 201203, CN-Kina Jia, Hong, 720 Cai Lun Road Building 4, Pudong Shanghai 201203, CN-Kina Dai, Guangxiu, 720 Cai Lun Road Building 4, Pudong Shanghai 201203, CN-Kina
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	Certain triazolopyrazines, compositions thereof and methods of use therefor
(56)	References Cited:	WO-A1-2007/132308 WO-A1-2011/020861










Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1. Minst én forbindelse som er valgt fra:**







5



10




15




20


2




5




10




3
























5



10












4









5

10







5




5



10




6



og/eller minst ett farmasøytisk akseptabelt salt derav.


10 2. Minst én forbindelse ifølge krav 1, som er valgt fra:



og/eller minst ett farmasøytisk akseptabelt salt derav.

20


3. Forbindelse ifølge krav 1, som er:



og/eller minst ett farmasøytisk akseptabelt salt derav.

5

4. Forbindelse ifølge krav 1, som er:



10 **5.** Sammensetning som omfatter minst én forbindelse ifølge et hvilket som helst av kravene 1 til 3, og/eller minst ett farmasøytisk akseptabelt salt derav og minst én farmasøytisk akseptabel bærer.

15 **6.** Minst én forbindelse ifølge et hvilket som helst av kravene 1 til 3, og/eller minst ett farmasøytisk akseptabelt salt derav, for anvendelse i terapi.

7. Minst én forbindelse ifølge et hvilket som helst av kravene 1 til 3, og/eller minst ett farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av kreft.

20 **8.** Minst én forbindelse ifølge et hvilket som helst av kravene 1 til 3, og/eller minst ett farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av kreft som angitt i krav 7, hvor kreften er valgt fra lungekreft, hode- og halskreft, tykktarmskreft, bukspyttkjertelkreft, tykktarmskreft, brystkreft, eggstokkreft, prostatakreft, magekreft, nyrekreft, leverkreft, hjernekreft, benkreft og leukemi.

25

9. Minst én forbindelse ifølge et hvilket som helst av kravene 1 til 3, og/eller minst ett farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av kreft som angitt i krav 7, hvor forbindelsen administreres sammen med et anti-neoplastisk middel.